A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years

Article Pediatrics

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

Amy S. Paller et al.

Summary: This study aimed to assess the laboratory outcomes of children aged 6 months to < 6 years with moderate-to-severe atopic dermatitis treated with dupilumab. The results suggest that routine laboratory monitoring is not required for children in this age group treated with dupilumab plus topical corticosteroids.

PEDIATRIC DRUGS (2023)

Add to Collection

Article Dermatology

Efficacy and Safety of Dupilumab Maintained in Adults=60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Jonathan I. Silverberg et al.

Summary: This study reported the efficacy and safety of dupilumab in patients aged ≥ 60 years with moderate-to-severe atopic dermatitis. The results showed significant improvements in skin lesions, symptoms, biomarkers, and quality of life in dupilumab-treated patients at week 16. The safety profile of dupilumab in patients aged ≥ 60 years was consistent with previous findings.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China

Nali Yang et al.

Summary: This study aimed to describe the safety and efficacy of dupilumab in pediatric patients and examined differences of efficacy with various doses. The results showed that dupilumab treatment had significant efficacy in children aged 6 months to 11 years with moderate-to-severe atopic dermatitis, and was also safe.

DERMATITIS (2023)

Add to Collection

Letter Dermatology

A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

Luca Stingeni et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Letter Dermatology

Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy

C. Colonna et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Dermatology

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

Andrew Blauvelt et al.

Summary: This study reports the long-term safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis. It shows that long-term treatment with dupilumab provides incremental clinical benefit while maintaining an acceptable safety profile. The optimal dosing regimen for this age group may be every 2 weeks, and continued treatment is necessary to maintain efficacy.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice

A. Lasek et al.

Summary: This study evaluated the effectiveness and safety of Dupilumab in the daily practice of children aged 6-11 with moderate-to-severe atopic dermatitis (AD). The results showed a significant decrease in disease severity scores after 3 months of treatment, as well as a lower frequency of adverse events compared to previous trials. However, the administration of injectable form may present challenges in this age group. Overall, Dupilumab is an effective and safe treatment option for children with moderate-to-severe AD.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Allergy

Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study

Angel D. Pagan et al.

Summary: This study reviewed the long-term treatment responses and adverse events of children and adolescents with atopic dermatitis (AD) treated with dupilumab. The results showed that dupilumab was effective and well-tolerated in treating pediatric and adolescent AD patients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

Article Medicine, General & Internal

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Amy S Paller et al.

LANCET (2022)

Add to Collection

Article Pediatrics

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

Maddalena Napolitano et al.

Summary: This study evaluated the effectiveness and safety of dupilumab in the treatment of children aged 6-11 years with atopic dermatitis. The results showed that dupilumab treatment significantly improved disease severity, itching, sleep, and quality of life.

PEDIATRIC DRUGS (2022)

Add to Collection

Article Dermatology

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

M. J. Cork et al.

Summary: The study demonstrates that dupilumab improves symptoms in children aged 6 to 12 with severe atopic dermatitis, showing acceptable safety and long-term efficacy. The drug concentration and safety were well validated in the study.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Cataldo Patruno et al.

Summary: The study evaluated the efficacy and safety of Dupilumab in treating elderly patients with atopic dermatitis over 52 weeks. Results showed a reduction in disease severity scores and a low rate of adverse events, indicating that Dupilumab is an effective and safe long-term treatment option for atopic dermatitis in patients aged over 65 years.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years

Related references

Export Citation

Share Paper